Trial Profile
A randomised cross-over trial to compare the time spent in euglycaemia in people with type 1 diabetes (T1D) during 5 consecutive days of continuous moderate-intensity exercise, on either 100% or 75% of their usual insulin degludec dose.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2019
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 22 Oct 2018 New trial record
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes